[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 37 of about 37
1. Takeuchi A, Tsuchiya H, Yamamoto N, Hayashi K, Yamauchi K, Kawahara M, Miyamoto K, Tomita K: Caffeine-potentiated chemotherapy for patients with high-grade soft tissue sarcoma: long-term clinical outcome. Anticancer Res; 2007 Sep-Oct;27(5B):3489-95
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Caffeine-potentiated chemotherapy for patients with high-grade soft tissue sarcoma: long-term clinical outcome.
  • BACKGROUND: Caffeine, which has a DNA-repair inhibiting effect, enhances the cytocidal effects of anticancer drugs and radiation.
  • The present study was performed to assess the efficacy of caffeine-potentiated chemotherapy for high-grade soft tissue sarcoma (STS).
  • PATIENTS AND METHODS: A non-randomised prospective clinical trial was initiated for 90 patients with non-metastatic (stages II and III) or metastatic (stage IV) STS.
  • A radiographic and histological response to chemotherapy was assessed.
  • The local recurrence rate was 23.7% in stages II and III and 13.6% in stage IV.
  • Lung metastases newly developed in 21 (35.6%) patients at stages II and III.
  • With a median follow-up period of 52 months, the overall 5-year cumulative survival rate at stages II and III was 80.7%.
  • Local recurrence-free survival for the histological responders and distant metastasis-free survival for the radiographic responders at stages II and III were significantly improved compared to the non-responders (p=0.004 and p=0.034).
  • CONCLUSION: Caffeine-potentiated chemotherapy resulted in a favourable radiographic response and prolonged overall survival of the patients at all stages.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Caffeine / therapeutic use. Sarcoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Disease-Free Survival. Drug Synergism. Female. Humans. Kaplan-Meier Estimate. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Staging. Preoperative Care. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Caffeine.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. CAFFEINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17972506.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 3G6A5W338E / Caffeine
  •  go-up   go-down


2. Ray-Coquard I, Biron P, Blay JY: [High-dose chemotherapy in soft tissue sarcomas of adults]. Bull Cancer; 2001 Sep;88(9):858-62
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [High-dose chemotherapy in soft tissue sarcomas of adults].
  • [Transliterated title] Chimiothérapie à hautes doses dans les sarcomes des tissus mous de l'adulte.
  • Few cytotoxic agents are active for the treatment of soft tissue sarcomas of adults: drugs active in monotherapy are doxorubicin, ifosfamide, dacarbazine and ET743.
  • In patients with advanced stage soft tissue sarcomas (ASTS), a dose-response relationship has been established for doxorubicin and ifosfamide.
  • Intensive combination chemotherapy regimens at conventional doses (MAID, or AI) yield higher objective response rates than monochemotherapy regimens, ranging between 25% and 44%, but failed improve survival rates as comparted to less intensive regimens.
  • Recently, several phase I or II studies have investigated the use of high dose chemotherapy regimens as consolidation therapy in ASTS in response to conventional regimens.
  • Some of these patients with ASTS achieved long term complete remission, in particular in the subgroup of patients in complete remission after conventional chemotherapy in advanced phase.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Sarcoma / drug therapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Clinical Trials, Phase I as Topic. Clinical Trials, Phase II as Topic. Dacarbazine / administration & dosage. Dioxoles / administration & dosage. Dose-Response Relationship, Drug. Doxorubicin / administration & dosage. Hematopoietic Stem Cell Transplantation. Humans. Ifosfamide / administration & dosage. Isoquinolines / administration & dosage. Tetrahydroisoquinolines

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11604358.001).
  • [ISSN] 0007-4551
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Dioxoles; 0 / Isoquinolines; 0 / Tetrahydroisoquinolines; 114899-77-3 / trabectedin; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; UM20QQM95Y / Ifosfamide
  • [Number-of-references] 40
  •  go-up   go-down


3. Meric F, Hess KR, Varma DG, Hunt KK, Pisters PW, Milas KM, Patel SR, Benjamin RS, Plager C, Papadopoulos NE, Burgess MA, Pollock RE, Feig BW: Radiographic response to neoadjuvant chemotherapy is a predictor of local control and survival in soft tissue sarcomas. Cancer; 2002 Sep 1;95(5):1120-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiographic response to neoadjuvant chemotherapy is a predictor of local control and survival in soft tissue sarcomas.
  • BACKGROUND: Downstaging of large soft tissue sarcomas can be accomplished by the use of neoadjuvant chemotherapy (NeoCT).
  • METHODS: The authors reviewed the medical records of 65 patients with Stage II or III soft tissue sarcoma (42 extremity, 23 retroperitoneal) who were treated with doxorubicin or ifosfamide-based NeoCT from January 1991 to December 1996.
  • Radiographic response and impact on surgical therapy were determined retrospectively by comparing imaging studies obtained before and after chemotherapy.
  • CONCLUSIONS: The NeoCT regimens used in this study resulted in tumor shrinkage sufficient to impact surgical therapy in a few patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoadjuvant Therapy. Neoplasm Recurrence, Local. Retroperitoneal Neoplasms / drug therapy. Sarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 American Cancer Society.
  • (PMID = 12209699.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Meyer T, McTiernan A, Whelan J: A Phase II Study of Docetaxel in Patients with Relapsed and Refractory Ewing's Tumours. Sarcoma; 2003;7(1):13-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A Phase II Study of Docetaxel in Patients with Relapsed and Refractory Ewing's Tumours.
  • Purpose. The prognosis for patients with Ewing's tumours who have metastases at presentation or who are refractory to standard chemotherapy regimens remains poor.
  • This report describes the initial results of a prospective phase II trial of docetaxel in patients with progressive or refractory Ewing's tumours.Patients and methods.
  • Fourteen patients with Ewing's tumours who had all relapsed or progressed after treatment with multi-drug cytotoxic therapy were treated with docetaxel 100 mg/m(2) infused over 1 h, three weekly for a maximum of six cycles.
  • The remaining patients progressed on treatment.
  • Further evaluation of its efficacy at an earlier stage of the disease is warranted.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1998 Sep;16(9):3044-52 [9738574.001]
  • [Cites] Ann Oncol. 1998 Mar;9(3):275-81 [9602261.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1413-24 [10334526.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1127 [10561170.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2341-54 [10561296.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(4):885-92 [10673532.001]
  • [Cites] Am J Clin Oncol. 2000 Apr;23(2):132-9 [10776972.001]
  • [Cites] Semin Oncol. 2000 Apr;27(2 Suppl 3):11-8 [10810933.001]
  • [Cites] J Clin Oncol. 2000 May;18(10):2081-6 [10811673.001]
  • [Cites] J Clin Oncol. 2000 Jun;18(12):2369-77 [10856096.001]
  • [Cites] J Natl Cancer Inst. 1991 Feb 20;83(4):288-91 [1671606.001]
  • [Cites] J Surg Oncol. 1991 May;47(1):37-40 [1902537.001]
  • [Cites] J Clin Oncol. 1990 Sep;8(9):1514-24 [2099751.001]
  • [Cites] Cancer. 1990 Sep 1;66(5):887-93 [2201433.001]
  • [Cites] Br J Cancer. 1977 Oct;36(4):511-22 [271010.001]
  • [Cites] Br J Cancer. 1995 Oct;72(4):1016-9 [7547214.001]
  • [Cites] Eur J Cancer. 1995;31A Suppl 4:S21-4 [7577101.001]
  • [Cites] J Clin Oncol. 1994 Sep;12(9):1748-53 [7916038.001]
  • [Cites] Ann Oncol. 1994 Jul;5(6):539-42 [7918126.001]
  • [Cites] N Engl J Med. 1994 Aug 4;331(5):294-9 [8022439.001]
  • [Cites] J Clin Oncol. 1993 Aug;11(8):1482-8 [8101562.001]
  • [Cites] Cancer. 1996 Aug 15;78(4):901-11 [8756388.001]
  • [Cites] Am J Clin Oncol. 1996 Dec;19(6):574-6 [8931674.001]
  • [Cites] J Clin Oncol. 1997 Apr;15(4):1538-43 [9193350.001]
  • [Cites] Clin Cancer Res. 1998 Feb;4(2):357-60 [9516923.001]
  • [Cites] J Clin Oncol. 1998 Nov;16(11):3628-33 [9817284.001]
  • (PMID = 18521364.001).
  • [ISSN] 1357-714X
  • [Journal-full-title] Sarcoma
  • [ISO-abbreviation] Sarcoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Other-IDs] NLM/ PMC2395514
  •  go-up   go-down


5. Verma S, Bramwell V: Dose-intensive chemotherapy in advanced adult soft tissue sarcoma. Expert Rev Anticancer Ther; 2002 Apr;2(2):201-15
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dose-intensive chemotherapy in advanced adult soft tissue sarcoma.
  • The treatment of metastatic soft tissue sarcomas in adults is one of the most challenging areas in oncology.
  • While multidisciplinary management of early-stage, localized disease has led to a number of improved outcomes, therapy of unresectable or advanced disease remains problematic.
  • Adriamycin and ifosfamide are the only chemotherapeutic drugs to have consistently produced response rates of over 20% when given as single agents and these two drugs have been exhaustively studied alone or in combination.
  • In this article, the status of dose-intensive chemotherapy in advanced adult soft tissue sarcomas (excluding pediatric histologies, such as Ewing's sarcoma and rhabdomyosarcoma) will be discussed.
  • Emphasis will be placed on data from randomized Phase III trials but information from Phase I/II studies will also be reviewed and recommendations will be made on a systematic analysis of the data.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Sarcoma / drug therapy
  • [MeSH-minor] Clinical Trials as Topic / methods. Clinical Trials as Topic / statistics & numerical data. Clinical Trials as Topic / trends. Dose-Response Relationship, Drug. Drug Administration Schedule. Humans. Lung Neoplasms / secondary. Lung Neoplasms / surgery

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12113242.001).
  • [ISSN] 1473-7140
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 103
  •  go-up   go-down


6. Maki RG, Kraft AS, Scheu K, Yamada J, Wadler S, Antonescu CR, Wright JJ, Schwartz GK: A multicenter Phase II study of bortezomib in recurrent or metastatic sarcomas. Cancer; 2005 Apr 1;103(7):1431-8
Hazardous Substances Data Bank. BORTEZOMIB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A multicenter Phase II study of bortezomib in recurrent or metastatic sarcomas.
  • METHODS: Two arms were opened, each using a Simon two-stage design.
  • Arm A included patients with osteogenic sarcoma, Ewing sarcoma, and rhabdomyosarcoma.
  • Arm B accrued patients with other types of soft tissue sarcomas.
  • Patients were not allowed to have received previous chemotherapy for metastatic disease.
  • Due to the inactivity of this agent, the study was closed after the first stage of accrual.
  • CONCLUSIONS: Bortezomib has minimal activity in soft tissue sarcoma as a single agent.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Bone Neoplasms / drug therapy. Boronic Acids / therapeutic use. Proteasome Inhibitors. Pyrazines / therapeutic use. Sarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Bortezomib. Drug Administration Schedule. Fatigue / chemically induced. Female. Humans. Male. Middle Aged. Neoplasm Metastasis / drug therapy. Neoplasm Recurrence, Local / drug therapy. Nervous System Diseases / chemically induced. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 American Cancer Society.
  • (PMID = 15739208.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CM / N01-CM17105; United States / NCI NIH HHS / CA / P01-CA47179
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Boronic Acids; 0 / Proteasome Inhibitors; 0 / Pyrazines; 69G8BD63PP / Bortezomib
  •  go-up   go-down


7. Tiwari A, Gupta H, Jain S, Kapoor G: Outcome of multimodality treatment of Ewing's sarcoma of the extremities. Indian J Orthop; 2010 Oct;44(4):378-83

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of multimodality treatment of Ewing's sarcoma of the extremities.
  • BACKGROUND: The management of Ewing's sarcoma family of tumors (ESFT, Ewing's sarcoma/primitive neuroectodermal tumor) has been established as a multimodality treatment.
  • Advances in imaging and diagnostics, chemotherapy, surgical techniques, radiotherapy and prosthetic technology have resulted in drastic changes in the outcome of this disease, with most of the recent studies having 5-year survival rates of more than 60%.
  • The Indian patients present at a more advanced stage and the compliance of treatment is suboptimal.
  • While there is plenty of data in the world literature on the outcome of Ewing's sarcoma, there is paucity of data in Indian patients.
  • Therefore, we conducted the present study to analyze the outcome of multimodality treatment of ESFT of the extremities at a tertiary nonprofit institute over a decade.
  • MATERIALS AND METHODS: 34 patients who had histopathologically proven diagnosis of Ewing's sarcoma of the extremities and had received treatment at our institute from 1997 through 2007 were included for analysis.
  • The majority of patients had involvement of the femur (35%), followed by tibia (17%), fibula and foot (15% each), humerus (12%) and soft tissue of thigh (6%).
  • Twenty-nine patients presented with localized disease (Enneking stage II B) while five patients presented with metastases (Enneking stage III).
  • All patients received Vincristine, Actinomycin D, Cyclofosfamide + Ifosfamide and Etoposide (VAC+IE)-based chemotherapy and local treatment was offered to all but three patients having multicentric disease.
  • The local treatment offered were, radiation (n= 15), surgery (n= 12) both surgery and radiation (n=4).
  • These outcomes were correlated with age, sex, size of tumor, stage at presentation, modality of local treatment and site of relapse.
  • On correlation with age, sex, size of tumor, stage at presentation, modality of local treatment and site of relapse, no correlation of survival was seen with any of the variables except event-free survival with size of the tumor.
  • CONCLUSION: Although the demographic profile, stage at presentation and the local and systemic treatment regimen followed in our study was similar to the world literature, the outcome of Ewing's sarcoma in Indian patients were found to be inferior to that reported in the western literature.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20924477.001).
  • [ISSN] 1998-3727
  • [Journal-full-title] Indian journal of orthopaedics
  • [ISO-abbreviation] Indian J Orthop
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2947723
  • [Keywords] NOTNLM ; Ewing’s sarcoma / extremity / multimodal chemotherapy
  •  go-up   go-down


8. Edmonson JH, Ryan LM, Falkson CI, Hicks DG, Blum RH: Phase II Study of Ifosfamide+Doxorubicin in Patients With Advanced Synovial Sarcomas (E1793): A Trial of the Eastern Cooperative Oncology Group. Sarcoma; 2003;7(1):9-11

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II Study of Ifosfamide+Doxorubicin in Patients With Advanced Synovial Sarcomas (E1793): A Trial of the Eastern Cooperative Oncology Group.
  • Purpose Because we had observed in the synovial sarcoma subgroup of a broad phase III advanced soft tissue sarcoma study a significantly greater objective regression rate from ifosfamide+doxorubicin (88%) than from doxorubicin alone (20%) (P = 0.02), the Eastern Cooperative Oncology Group (ECOG) decided to further assess this two drug combination in a subsequent Phase II study.Patients Between 1994 and 1999, twelve adult patients with advanced synovial sarcomas were enrolled to receive, as their initial chemotherapy, ifosfamide 7.5 gm/m(2) plus doxorubicin 60 mg/m(2), given intravenously over two consecutive days every 3 weeks.Methods Each day for 2 days doxorubicin 30 mg/m(2) was infused over 5 min through a running i.v., followed by ifosfamide 3750 mg/m(2) over 4 h.
  • Continuous i.v. fluid was infused at 300 mL/h for 3 h on day 1, before chemotherapy was begun; then the infusion was continued at 100 mL/h for a total of 3 days.
  • Mesna 750 mg/m(2) was given 15 min before ifosfamide and at 4 and 8 h after ifosfamide on days 1 and 2 of each treatment cycle.
  • Filgrastim (G-CSF) 5 mug/kg was given subcutaneously each day for 14 days beginning on day 3 of each treatment cycle to limit the severity of neutropenia.Results Five of our 12 patients (42%) experienced partial regression of their advanced synovial sarcomas; however, this first stage result was borderline for proceeding to the second planned stage of accrual and our case accrual was quite poor.
  • Thus, the study was closed after stage one accrual.
  • Our patients received a median of four cycles of chemotherapy (range: 1 to 6).
  • All patients experienced at least grade 3 neutropenia (grade 4 in nine of them), and one patient died of treatment-related sepsis following the initial cycle of chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Jan;17(1):150-7 [10458228.001]
  • [Cites] J Clin Oncol. 2000 May;18(10):2087-94 [10811674.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):525-34 [11208847.001]
  • [Cites] Cancer Res. 2002 Jan 1;62(1):135-40 [11782370.001]
  • [Cites] J Clin Oncol. 1993 Jul;11(7):1269-75 [8315424.001]
  • [Cites] Cancer. 1989 Jul 15;64(2):484-90 [2736494.001]
  • [Cites] J Clin Oncol. 1994 Nov;12(11):2360-6 [7964951.001]
  • [Cites] Cancer. 1994 May 15;73(10):2506-11 [8174046.001]
  • [Cites] J Clin Oncol. 2002 Mar 15;20(6):1692-703 [11896121.001]
  • (PMID = 18521363.001).
  • [ISSN] 1357-714X
  • [Journal-full-title] Sarcoma
  • [ISO-abbreviation] Sarcoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Other-IDs] NLM/ PMC2395511
  •  go-up   go-down


9. Andrés AM, Avila LF, Luis AL, Encinas JL, Sastre A, López-Gutiérrez JC, Martínez L, Queizán A, Martínez-Urrutia MJ, Jaureguizar E, Tovar JA: [Soft tissue sarcomas (1991-2004)]. Cir Pediatr; 2006 Oct;19(4):210-6
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Soft tissue sarcomas (1991-2004)].
  • BACKGROUND: The aim of this study is to review the results of the treatment of soft tissue sarcomas (STS) in our Department during the last 13 years.
  • MATERIAL AND METHODS: Fifty-seven children (39 rhabdomyosarcomas (RMS) and 18 other types of sarcomas) have been treated.
  • The charts of 39 chidren were analysed evaluating several parameters (age, sex, location, histology, initial stage, clinical and surgical treatment and results) as prognostic factors using actuarial survival analyses and log-rank tests.
  • At diagnosis, 74% were in stages I or II.
  • Surgical biopsy was made before the definitive surgery in 12 cases.
  • Only 9 received chemotherapy and one radiotherapy.
  • [MeSH-major] Sarcoma / epidemiology. Soft Tissue Neoplasms / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17352109.001).
  • [ISSN] 0214-1221
  • [Journal-full-title] Cirugía pediátrica : organo oficial de la Sociedad Española de Cirugía Pediátrica
  • [ISO-abbreviation] Cir Pediatr
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


10. Brady MS, Brown K, Patel A, Fisher C, Marx W: A phase II trial of isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft tissue sarcoma of the extremity. Ann Surg Oncol; 2006 Aug;13(8):1123-9
Hazardous Substances Data Bank. DACTINOMYCIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II trial of isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft tissue sarcoma of the extremity.
  • BACKGROUND: Isolated limb infusion (ILI) is a minimally invasive technique of delivering regional chemotherapy in patients with advanced melanoma or soft tissue sarcoma of the limb.
  • Reports from Australia of efficacy similar to that of isolated limb perfusion prompted us to conduct a phase II trial to evaluate the efficacy and safety of ILI.
  • METHODS: Eligible patients had American Joint Committee on Cancer stage IIIB or IIIC melanoma or unresectable soft tissue sarcoma of the limb.
  • No patient developed compartment syndrome or required amputation.
  • [MeSH-major] Chemotherapy, Cancer, Regional Perfusion / methods. Melanoma / drug therapy. Sarcoma / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Angiography. Dactinomycin / administration & dosage. Extremities. Female. Humans. Male. Melphalan / administration & dosage. Middle Aged. Neoplasm Recurrence, Local. Treatment Outcome


11. Sleijfer S, Ray-Coquard I, Papai Z, Le Cesne A, Scurr M, Schöffski P, Collin F, Pandite L, Marreaud S, De Brauwer A, van Glabbeke M, Verweij J, Blay JY: Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol; 2009 Jul 1;27(19):3126-32
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043).
  • PURPOSE Given the importance of angiogenesis in soft tissue sarcoma (STS), pazopanib, an oral angiogenesis inhibitor that targets vascular endothelial growth factor receptor and platelet-derived growth factor receptor, was explored in patients with advanced STS.
  • PATIENTS AND METHODS Patients with intermediate- or high-grade advanced STS who were ineligible for chemotherapy or who had received no more than two prior cytotoxic agents for advanced disease, who had documented progression, who had adequate performance status, and who had good organ function were eligible.
  • Four different strata were studied: adipocytic STS, leiomyosarcomas, synovial sarcomas, and other STS types.
  • A Simon two-stage design was applied (P1 = 40%; P0 = 20%; alpha = beta = .1) for each stratum.
  • The adipocytic STS stratum was closed after the first stage, given insufficient activity (PFR(12 weeks), five [26%] of19).
  • PFR(12 weeks) was 18 (44%) of 41 patients in the leiomyosarcoma cohort, 18 (49%) of 37 in the synovial sarcomas, and 16 (39%) of 41 in the other STS types.
  • Compared with historical controls who were treated with second-line chemotherapy, progression-free and overall survivals were prolonged in the three cohorts in which the primary end point was reached.
  • The most frequent drug-related toxicities were hypertension, fatigue, hypopigmentation, and nausea.
  • CONCLUSION Pazopanib is well tolerated in patients with relapsed, advanced STS and demonstrates interesting activity that warrants additional study in patients with leiomyosarcomas, synovial sarcomas, and other STS types.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Pyrimidines / therapeutic use. Sarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy. Sulfonamides / therapeutic use
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / mortality

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • Genetic Alliance. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19451427.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Pyrimidines; 0 / Sulfonamides; 7RN5DR86CK / pazopanib
  •  go-up   go-down


12. Tanaka K, Kawamoto H, Saito I, Yoshimura K, Fukuda H, Iwamoto Y: Preoperative and postoperative chemotherapy with ifosfamide and adriamycin for adult high-grade soft-tissue sarcomas in the extremities: Japan Clinical Oncology Group Study JCOG0304. Jpn J Clin Oncol; 2009 Apr;39(4):271-3
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative and postoperative chemotherapy with ifosfamide and adriamycin for adult high-grade soft-tissue sarcomas in the extremities: Japan Clinical Oncology Group Study JCOG0304.
  • This phase II clinical trial aims to evaluate the efficacies and toxicities of pre- and postoperative chemotherapy with adriamycin plus ifosfamide on the patients with soft-tissue high-grade sarcomas.
  • Patients who have operable, non-round cell soft-tissue sarcomas [French Federation of Cancer Center (FNCLCC) Grades 2 and 3] arising in the extremities [T2bN0M0, i.e.
  • American Joint Committee on Cancer (AJCC) stage III] are treated by three courses of preoperative chemotherapy consisting of adriamycin and ifosfamide followed by complete resection and additional two courses of the same chemotherapy regimen.
  • The Bone and Soft Tissue Tumor Study Group (BSTTSG) in the Japan Clinical Oncology Group (JCOG) including 26 specialized institutes will accrue 75 patients.
  • The primary endpoint of the study is the 2-year progression-free survival rate, and secondary endpoints are response rate of the preoperative chemotherapy, 3-year progression-free survival rate, progression-free survival, overall survival and adverse events.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Doxorubicin / administration & dosage. Ifosfamide / administration & dosage. Sarcoma / drug therapy

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19155282.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 80168379AG / Doxorubicin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


13. Chidiac T, Budd GT, Pelley R, Sandstrom K, McLain D, Elson P, Crownover R, Marks K, Muschler G, Joyce M, Zehr R, Bukowski R: Phase II trial of liposomal doxorubicin (Doxil) in advanced soft tissue sarcomas. Invest New Drugs; 2000 Aug;18(3):253-9
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of liposomal doxorubicin (Doxil) in advanced soft tissue sarcomas.
  • PURPOSE: To assess the objective response rate, toxicity experienced, progression-free survival, and overall survival of patients with previously untreated advanced soft tissue sarcomas treated with a liposomal doxorubicin formulation (Doxil).
  • METHODS: Patients with metastatic or recurrent soft tissue sarcoma who had received no prior chemotherapy for advanced disease were treated with liposomal doxorubicin (Doxil) according to a two stage accrual design.
  • The median time to progression was 1.9 months (range 0.9-6.2).
  • CONCLUSION: Though well-tolerated, Doxil given according to this dose and schedule to patients with advanced soft tissue sarcoma had no significant therapeutic activity.
  • Future investigations of Doxil in soft tissue sarcomas should use a different schedule and dose.
  • [MeSH-major] Doxorubicin / administration & dosage. Sarcoma / drug therapy
  • [MeSH-minor] Adult. Aged. Drug Carriers. Female. Follow-Up Studies. Humans. Liposomes. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 1978 Mar;187(3):332-6 [637593.001]
  • [Cites] J Clin Oncol. 1998 Jul;16(7):2445-51 [9667262.001]
  • [Cites] Pharm Res. 1993 May;10(5):703-8 [8321835.001]
  • [Cites] J Clin Oncol. 1989 Nov;7(11):1655-9 [2681554.001]
  • [Cites] J Clin Oncol. 1997 Oct;15(10):3185-91 [9336354.001]
  • [Cites] Cancer Chemother Pharmacol. 1991;28(4):259-65 [1678995.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1992 Jan;4(1):32-5 [1736976.001]
  • [Cites] Cancer. 1982 Dec 15;50(12):2757-62 [7139566.001]
  • [Cites] Cancer. 1990 Sep 1;66(5):862-7 [2201431.001]
  • [Cites] Cancer Res. 1994 Feb 15;54(4):987-92 [8313389.001]
  • [Cites] J Clin Pharmacol. 1996 Jan;36(1):55-63 [8932544.001]
  • [Cites] J Clin Oncol. 1997 Mar;15(3):987-93 [9060537.001]
  • [Cites] J Clin Oncol. 1995 Jul;13(7):1777-85 [7602367.001]
  • [Cites] J Clin Oncol. 1987 Jun;5(6):840-50 [3585441.001]
  • [Cites] Biochim Biophys Acta. 1991 Jul 1;1066(1):29-36 [2065067.001]
  • [Cites] J Clin Oncol. 1998 Feb;16(2):683-91 [9469358.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2111-7 [9164225.001]
  • [Cites] J Clin Oncol. 1987 Jun;5(6):851-61 [3295129.001]
  • [Cites] Ann Oncol. 1998 Oct;9(10):1131-3 [9834828.001]
  • [Cites] Cancer. 1973 Jul;32(1):1-8 [4716773.001]
  • [Cites] Cancer. 1977 May;39(5):1940-8 [858124.001]
  • [Cites] Biochem Biophys Res Commun. 1992 Sep 16;187(2):1098-105 [1356335.001]
  • [Cites] Ann Oncol. 1998 Jul;9(7):711-6 [9739435.001]
  • [Cites] Cancer. 1974 Jan;33(1):19-27 [4810094.001]
  • [Cites] J Clin Oncol. 1993 Jul;11(7):1269-75 [8315424.001]
  • (PMID = 10958594.001).
  • [ISSN] 0167-6997
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Drug Carriers; 0 / Liposomes; 80168379AG / Doxorubicin
  •  go-up   go-down


14. Pisters PW, O'Sullivan B, Maki RG: Evidence-based recommendations for local therapy for soft tissue sarcomas. J Clin Oncol; 2007 Mar 10;25(8):1003-8
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evidence-based recommendations for local therapy for soft tissue sarcomas.
  • There has been a gradual migration in the local treatment of soft tissue sarcomas from amputation and similar radical resectional approaches to more conservative, function-preserving surgery combined with radiotherapy.
  • In the new millennium, attention has shifted to defining subsets of patients who might be adequately treated by surgery alone and defining the optimal sequence of surgery and radiation for patients who require both types of local therapy.
  • There remains considerable discussion and debate surrounding the issue of pre- and postoperative chemotherapy for patients with localized soft tissue sarcomas.
  • Adjuvant chemotherapy is a standard of care for adults who have the subtypes of soft tissue sarcomas that typically occur in pediatric patients (Ewing sarcoma, rhabdomyosarcoma), and just as clearly, adjuvant chemotherapy is not warranted in patients with low- and intermediate-risk disease (stages I and II).
  • For patients with higher risk disease (stage III), the available randomized trials do not convincingly demonstrate a clinical benefit to adjuvant chemotherapy.
  • As such, a complete accounting of potential risks and benefits is appropriate when discussing adjuvant chemotherapy with patients who have stage III disease.
  • [MeSH-major] Sarcoma / therapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Combined Modality Therapy. Evidence-Based Medicine. Humans. Randomized Controlled Trials as Topic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17350950.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 37
  •  go-up   go-down


15. Gadducci A, Romanini A: Adjuvant chemotherapy in early stage uterine sarcomas: an open question. Eur J Gynaecol Oncol; 2001;22(5):352-7
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant chemotherapy in early stage uterine sarcomas: an open question.
  • Uterine sarcomas are aggressive gynecological cancers even at early stage of disease.
  • The most common histological types are represented by leiomyosarcoma, endometrial stromal sarcoma, and carcinosarcoma.
  • The mainstay of treatment of stage I-II disease is total hysterectomy with bilateral salpingo-oophorectomy.
  • Adjuvant chemotherapy is a logical approach, since distant recurrences are more frequent than local failures.
  • The chemotherapy regimens commonly used in advanced uterine sarcomas are similar to the ones for advanced soft tissue sarcomas, with anthracyclines and ifosfamide as the most active drugs.
  • It is advisable to design international cooperative randomized trials with the aim of defining the role of adjuvant chemotherapy in the treatment of early stage uterine sarcomas.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Sarcoma / drug therapy. Uterine Neoplasms / drug therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Female. Humans. Neoplasm Staging. Radiotherapy, Adjuvant. Randomized Controlled Trials as Topic

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11766739.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 100
  •  go-up   go-down


16. Morgan JA, George S, Desai J, St Amand M, Horton D, Wilkins E, Manola J, Demetri GD: Phase II study of gemcitabine/vinorelbine (GV) as first or second line chemotherapy in patients with metastatic soft tissue sarcoma (STS). J Clin Oncol; 2004 Jul 15;22(14_suppl):9009

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of gemcitabine/vinorelbine (GV) as first or second line chemotherapy in patients with metastatic soft tissue sarcoma (STS).
  • : 9009 Background: Both single agent gemcitabine and vinorelbine have efficacy for treatment of STS.
  • Combination GV is active therapy for metastatic carcinoma, with acceptable toxicity.
  • This single institution phase II trial has been undertaken to determine response rates and toxicity of combination GV for treatment of metastatic STS.
  • RESULTS: An initial 18 pts have been accrued, following standard two-stage design by the method of Simon.
  • Histology was uterine or extremity leiomyosarcoma (LMS) in 9, high grade pleomorphic sarcoma in 2, and 1 each with carcinosarcoma, pleomorphic liposarcoma, malignant peripheral nerve sheath tumor (MPNST), desmoplastic small round cell tumor, rhabdomyosarcoma, and small round cell sarcoma.
  • No treatment related deaths have occurred.
  • Of the remaining 9, 4 have been treatment related, including cough, nausea, vomiting, and SGPT elevation.
  • There have been two confirmed PRs, one high grade uterine LMS progressing after single agent doxorubicin, and one small round cell tumor recurring within 6 months of completion of a 5 drug Ewing's regimen.
  • Median time to progression has been 4.2 months and median survival 6.25 months.
  • CONCLUSIONS: GV appears to be a well-tolerated and potentially effective regimen for first or second line treatment of metastatic STS.
  • Further accrual to this Phase II study is warranted.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28013692.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. von Mehren M, Chu Q, Alcindor T, Townsley C, Thallury S, MacAlpine K, Wright JJ, Oza A: Early results of a PMH Phase II Consortium trial of AZD0530 in advanced soft tissue sarcoma (STS). J Clin Oncol; 2009 May 20;27(15_suppl):10579

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early results of a PMH Phase II Consortium trial of AZD0530 in advanced soft tissue sarcoma (STS).
  • Advanced STS have limited therapeutic options; therefore we tested the efficacy of AZD0530 in advanced STS.
  • METHODS: The study utilized a Simon Two stage design with the primary endpoint be objective tumor response + prolonged stable disease rate (defined as partial/complete response by RECIST, or stable disease >4 months).
  • Patients with measurable advanced STS with up to one prior chemotherapy for metastatic disease were eligible for study participation following informed consent.
  • Patients were excluded for cardiac dysfunction, poorly controlled hypertension, inability to swallow or absorb medication.
  • Patients had pulmonary function tests at baseline that were repeated within the first 4 weeks of therapy.
  • RESULTS: 17 patients (11 F, 6M) with advanced STS (leiomyosarcoma 5, rhabdomyosarcoma 3, MFH/carcinosarcoma/Fibrosarcoma 2, endometrial stromal sarcoma/liposarcoma/non-rhabdoSTS 1 each) were enrolled, the majority of whom had prior therapy (14 chemo and 9 xrt).
  • Nine discontinued therapy for progressive disease, 2 for toxicity and 1 patient request.
  • Median time to progression in the 13 patients was 1.7 months.
  • No drug related pulmonary toxicity has been observed.
  • Further testing may be warranted in selected tumors in combination with chemotherapy given pre-clinical synergy data or in tumors pre-selected for target expression.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963760.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Clisant S, Adenis A, Dansin E, Desauw C, Degardin M, Mortier L, Fournier C, Penel N: Oral metronomic chemotherapy using cyclophosphamide in metastatic patients (pts) after standard treatment: Results of a randomized phase II trial. J Clin Oncol; 2009 May 20;27(15_suppl):e13519

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oral metronomic chemotherapy using cyclophosphamide in metastatic patients (pts) after standard treatment: Results of a randomized phase II trial.
  • : e13519 Background: Oral metronomic chemotherapy (OMC) has antiangiogenic properties and megestrol acetate (MA) is an orexigen used to maintain the general condition in critically ill pts.
  • Anecdotal responses have been reported with each treatment.
  • We hypothesized that each treatment offer disease control without significant severe toxicity.
  • METHODS: This multi-center-randomized study was aimed to assess the efficacy and tolerance of both treatments.
  • Main eligibility criteria were as follows: non-breast cancer, pts with progressive disease refractory to standard therapies or without established standard care, ECOG=0-1, neither hypercalcemia nor hypoalbuminemia.
  • The second stage was allowed because at least 2mSD were seen among 12 first pts.
  • Most common primaries were: colorectal cancer (30 pts), soft tissue sarcoma (17), lung cancer (13), head & neck (8) and unknown primaries (4).
  • The median number of previous lines of treatment was 4 (0-10).
  • Treatment was discontinued in 1 case because of MA- induced deep venous thrombosis.
  • The non-progression rate with OMC (15%) is in a same range of efficacy that was recently reported with new targeted therapy or anti-angiogenic agents administered in such pts.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961314.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Mita AC, Sankhala K, Sarantopoulos J, Carmona J, Okuno S, Goel S, Chugh R, Coffey MC, Mettinger K, Mita MM: A phase II study of intravenous (IV) wild-type reovirus (Reolysin) in the treatment of patients with bone and soft tissue sarcomas metastatic to the lung. J Clin Oncol; 2009 May 20;27(15_suppl):10524

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of intravenous (IV) wild-type reovirus (Reolysin) in the treatment of patients with bone and soft tissue sarcomas metastatic to the lung.
  • In vitro and in vivo studies with Reolysin in sarcoma cell lines revealed significant antitumor activity.
  • METHODS: This phase II open-label, single agent study was designed to characterize the efficacy and safety of Reolysin given IV every 28 days in patients (pts) with bone or soft tissue sarcoma with lung metastasis using a Simon two-stage design.
  • 38 pts were accrued to the first stage.
  • 38 pts received prior chemotherapy, radiotherapy, biological agents or combinations for their metastatic disease, 15 pts received more than 3 chemotherapy regimens.
  • The sarcoma subtypes included: synovial sarcoma (13 pts), osteosarcoma (7 pts), leiomyosarcoma (7 pts), MFH (5 pts), Ewing/PNET (1 pt), chordoma (1 pt), others (9 pts).
  • CONCLUSIONS: Utilization of single agent reovirus for treatment of sarcoma is a novel and unique therapeutic approach to date.
  • Reolysin is well tolerated and shows promise for the treatment of metastatic sarcoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963913.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Seddon BM, Scurr MR, Jones RL, Wood Z, Propert-Lewis C, A'Hern R, Whelan JS, Judson IR: Phase II study of gemcitabine and docetaxel as first-line chemotherapy in locally advanced/metastatic leiomyosarcoma. J Clin Oncol; 2009 May 20;27(15_suppl):10528

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of gemcitabine and docetaxel as first-line chemotherapy in locally advanced/metastatic leiomyosarcoma.
  • : 10528 Background: Locally advanced/metastatic soft tissue sarcoma is invariably incurable with a poor prognosis.
  • This study aims to investigate the combination as first line treatment in patients with unresectable incurable leiomyosarcoma.
  • Patients were evaluated for response by RECIST after cycles 2, 4, 6, and 8, and three-monthly after completing treatment.
  • The study was conducted with a Simon 2-stage design, recruiting 19 patients in stage 1, and 25 patients in stage 2.
  • Eligible patients had histologically proven leiomyosarcoma of the uterus (48.9%) or other sites (51.1%) unresectable for cure, with measurable disease, no previous chemotherapy, adequate organ function, and performance status 0-2.
  • Further investigation comparing the combination with current standard therapies for leiomyosarcoma is warranted.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963919.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Khanfir K, Alzieu L, Terrier P, Le Péchoux C, Bonvalot S, Vanel D, Le Cesne A: Does adjuvant radiation therapy increase loco-regional control after optimal resection of soft-tissue sarcoma of the extremities? Eur J Cancer; 2003 Sep;39(13):1872-80
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does adjuvant radiation therapy increase loco-regional control after optimal resection of soft-tissue sarcoma of the extremities?
  • Adjuvant radiotherapy (RT) is routinely recommended for most soft-tissue sarcomas (STS) of the extremities.
  • The median tumour size was 6 cm (range 1-20 cm) with 28, 44 and 28% of stage I, II and III lesions, respectively.
  • Other patient characteristics (age, tumour size, stage, deep-seated lesion, histoprognostic grade, adjuvant chemotherapy) were similar in both the RT and no-RT groups.
  • Adjuvant RT is indicated after mR resection and for residual tumour after definitive surgery, but its role after oR resection (primary resection or no residual tumour after re-excision) should be evaluated in a prospective randomised trial.
  • [MeSH-major] Sarcoma / radiotherapy. Soft Tissue Neoplasms / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Extremities. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local. Neoplasm Staging. Postoperative Care / methods. Radiotherapy, Adjuvant. Retrospective Studies. Survival Analysis. Time Factors

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12932665.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


22. Sun L, Wu LY, Li XG, Bai P, Zhang HT: [Clinical characterization of vulvar epithelioid sarcoma]. Zhonghua Zhong Liu Za Zhi; 2010 Dec;32(12):935-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical characterization of vulvar epithelioid sarcoma].
  • OBJECTIVE: Vulvar epithelioid sarcoma is a rare, undifferentiated soft-tissue sarcoma, with a high rate of local relapse, regional nodal spread and distant metastases.
  • The aim of this study was to investigate the clinical features, diagnosis, treatment and prognosis of this malignancy.
  • METHODS: We studied the clinicopathologic features of 20 cases of vulvar epithelioid sarcoma, of which 4 cases were admitted to our hospital from 1999 to 2009.
  • Seven patients were treated without adjuvant therapy.
  • Seven patients received postoperative radiotherapy only and three underwent chemotherapy.
  • Chemotherapy plus radiotherapy were given postoperatively in three.
  • 2 patients developed lymph node metastases but alive.
  • Survival of the early stage (I-II) patients was significantly longer than those in the advanced stage (III-IV) (median, 21 vs. 6 months, P < 0.01).
  • Radical local excision with adequate margin (at least 2 cm) and bilateral inguinofemoral lymphadenectomy is effective for the treatment of vulvar epithelioid sarcoma.
  • The role of adjuvant therapy, chemotherapy and radiation remains unclear but merits consideration.
  • [MeSH-major] Sarcoma / pathology. Sarcoma / surgery. Soft Tissue Neoplasms / pathology. Soft Tissue Neoplasms / surgery. Vulvar Neoplasms / pathology. Vulvar Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Humans. Keratins / metabolism. Lymph Node Excision. Lymphatic Metastasis. Middle Aged. Mucin-1 / metabolism. Neoplasm Staging. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate. Vimentin / metabolism. Vulva / surgery. Young Adult


23. Orbach D, Rey A, Oberlin O, Sanchez de Toledo J, Terrier-Lacombe MJ, van Unnik A, Quintana E, Stevens MC: Soft tissue sarcoma or malignant mesenchymal tumors in the first year of life: experience of the International Society of Pediatric Oncology (SIOP) Malignant Mesenchymal Tumor Committee. J Clin Oncol; 2005 Jul 1;23(19):4363-71
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soft tissue sarcoma or malignant mesenchymal tumors in the first year of life: experience of the International Society of Pediatric Oncology (SIOP) Malignant Mesenchymal Tumor Committee.
  • Sixty-four patients had rhabdomyosarcoma (RMS), 26 had undifferentiated sarcoma, and 12 had other histology.
  • Clinical TNM stage was stage I (41%), II (39%), III (6%), and IV (14%).
  • First-line treatment was ifosfamide, vincristine, dactinomycin, whereas the second-line combination consisted of either cisplatin and doxorubicin (in MMT 84) or vincristine, carboplatin, etoposide/teniposide (in MMT 89).
  • Chemotherapy doses were adapted to age.
  • Local therapy was conservative surgery as often as possible.
  • Only two of 13 stage IV patients survived.
  • CONCLUSION: OS was satisfactory even when local treatment was not aggressive, although the prognosis was poor for infants with alveolar RMS or metastatic tumors.
  • Chemotherapy toxicity was manageable with appropriate dose modification.
  • [MeSH-major] Sarcoma / drug therapy
  • [MeSH-minor] Age Factors. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Cyclophosphamide / therapeutic use. Dactinomycin / therapeutic use. Doxorubicin / administration & dosage. Epirubicin / therapeutic use. Etoposide / administration & dosage. Humans. Ifosfamide / therapeutic use. Infant. Infant, Newborn. Neoplasm Metastasis. Neoplasm Recurrence, Local. Rhabdomyosarcoma / drug therapy. Survival Analysis. Teniposide / administration & dosage. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Malignant mesenchymal tumor.
  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. TENIPOSIDE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15994146.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 1CC1JFE158 / Dactinomycin; 3Z8479ZZ5X / Epirubicin; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 957E6438QA / Teniposide; UM20QQM95Y / Ifosfamide; CEV protocol; IVA protocol
  •  go-up   go-down


24. Schöffski P, Blay JY, De Greve J, Brain E, Machiels JP, Soria JC, Sleijfer S, Wolter P, Ray-Coquard I, Fontaine C, Munzert G, Fritsch H, Hanft G, Aerts C, Rapion J, Allgeier A, Bogaerts J, Lacombe D: Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI). Eur J Cancer; 2010 Aug;46(12):2206-15
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI).
  • We performed a multi-centre, multi-tumour phase II trial to investigate the efficacy, safety and pharmacokinetics of BI 2536 in five solid tumour types.
  • PATIENTS AND METHODS: Patients with advanced head and neck, breast and ovarian cancer, soft tissue sarcoma and melanoma were selected according to protocol-defined general and tumour-specific criteria.
  • They were 18years old, had a good performance status, adequate bone marrow, renal and liver function, measurable progressive disease and had completed other relevant systemic treatments >4weeks ago.
  • The study was based on a Simon two-stage design, with 12 patients entering in stage 1 and additional 25 patients to be entered in case of at least one response in the first stage.
  • RESULTS: Seventy six patients were included, 71 started treatment and received a median number of two cycles (four in ovarian cancer).
  • CONCLUSIONS: BI 2536 showed limited antitumour activity according to the design of this trial in five different tumour types.
  • Derivatives of BI 2536 with a more favourable pharmacological profile are currently explored further in prospective studies.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Neoplasms / drug therapy. Pteridines / administration & dosage
  • [MeSH-minor] Adult. Aged. Breast Neoplasms / drug therapy. Breast Neoplasms / metabolism. Feasibility Studies. Female. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / metabolism. Humans. Infusions, Intravenous. Male. Melanoma / drug therapy. Melanoma / metabolism. Middle Aged. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / metabolism. Patient Compliance. Sarcoma / drug therapy. Sarcoma / metabolism. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20471824.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / BI 2536; 0 / Pteridines
  •  go-up   go-down


25. Chu QS, Forouzesh B, Syed S, Mita M, Schwartz G, Cooper J, Curtright J, Rowinsky EK: A phase II and pharmacological study of the matrix metalloproteinase inhibitor (MMPI) COL-3 in patients with advanced soft tissue sarcomas. Invest New Drugs; 2007 Aug;25(4):359-67
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II and pharmacological study of the matrix metalloproteinase inhibitor (MMPI) COL-3 in patients with advanced soft tissue sarcomas.
  • This phase II study evaluated the antitumor activity of the tetracycline analog COL-3, a potent inhibitor of metalloproteinases (MMPs), particularly MMP-2 and MMP-9, on a continuous oral schedule at a dose of 50 mg/m2 daily in patients with advanced and/or metastatic soft tissue sarcoma (STS).
  • The principal endpoints were the rate of objective tumor regression and the proportion of patients who did not experience disease progression during the first 8 weeks of treatment.
  • Other study objectives included an assessment of pharmacology of COL-3, time to progression (TTP), and overall survival.
  • A Simon two-stage design with multinomial stopping rule was employed, with 15 patients enrolled during the first stage of the study.
  • Although COL-3 was generally well-tolerated, there were no objective responses and 5(33%) patients experienced disease progression during the first 8 weeks of treatment, which exceeded the criteria established a priori with regard to pursuing further evaluations of COL-3 in STS.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Antineoplastic Agents / therapeutic use. Gastrointestinal Stromal Tumors / drug therapy. Sarcoma / drug therapy. Tetracyclines / pharmacology. Tetracyclines / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Endpoint Determination. Female. Humans. Male. Matrix Metalloproteinase Inhibitors. Middle Aged. Neoplasm Recurrence, Local. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Invest New Drugs. 2007 Aug;25(4):357. Copper, Joshua [corrected to Cooper, Joshua]
  • [Cites] J Pathol. 1998 Jul;185(3):256-61 [9771478.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]
  • [Cites] Blood. 1999 Jun 15;93(12):4031-3 [10361099.001]
  • [Cites] J Clin Oncol. 2006 Mar 20;24(9):1389-94 [16549833.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1272-5 [11245418.001]
  • [Cites] Semin Perinatol. 1991 Apr;15(2):118-26 [1652159.001]
  • [Cites] Clin Cancer Res. 2004 Mar 15;10(6):1971-5 [15041714.001]
  • [Cites] J Clin Oncol. 2002 Nov 15;20(22):4434-9 [12431965.001]
  • [Cites] Ann N Y Acad Sci. 1999 Jun 30;878:678-82 [10415806.001]
  • [Cites] Int J Cancer. 2002 Mar 10;98(2):297-309 [11857423.001]
  • [Cites] Cancer Res. 1997 Nov 1;57(21):4882-8 [9354453.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):584-92 [11208854.001]
  • [Cites] Int J Pancreatol. 1997 Feb;21(1):1-12 [9127168.001]
  • [Cites] J Clin Oncol. 2000 Mar;18(5):1135-49 [10694567.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):842-9 [15681529.001]
  • [Cites] Int J Cancer. 1993 Jun 19;54(4):614-8 [8514452.001]
  • [Cites] J Biopharm Stat. 1999 May;9(2):351-63 [10379698.001]
  • [Cites] Arch Dermatol. 2001 Apr;137(4):471-4 [11295928.001]
  • [Cites] Curr Treat Options Oncol. 2003 Dec;4(6):441-51 [14585225.001]
  • [Cites] J Clin Oncol. 2002 Jan 1;20(1):153-9 [11773164.001]
  • [Cites] Int J Cancer. 1991 Nov 11;49(5):666-72 [1657796.001]
  • [Cites] J Natl Cancer Inst. 2001 Feb 7;93(3):178-93 [11158186.001]
  • [Cites] J Cell Biol. 1992 Sep;118(5):1271-82 [1512297.001]
  • [Cites] Drugs. 2005;65(2):167-78 [15631540.001]
  • [Cites] J Am Board Fam Pract. 2002 May-Jun;15(3):239-41 [12038732.001]
  • [Cites] J Clin Oncol. 2005 Apr 20;23(12):2831-9 [15837997.001]
  • [Cites] Eur J Cancer. 2002 Mar;38(4):543-9 [11872347.001]
  • [Cites] Curr Med Chem. 2001 Feb;8(3):261-70 [11172681.001]
  • [Cites] Exp Cell Res. 2002 Apr 15;275(1):110-21 [11925109.001]
  • [Cites] Semin Oncol. 2000 Aug;27(4):420-3 [10950368.001]
  • [Cites] Pathobiology. 1998;66(1):5-16 [9577961.001]
  • [Cites] Am J Pathol. 1996 Jul;149(1):273-82 [8686751.001]
  • [Cites] Cochrane Database Syst Rev. 2003;(3):CD003293 [12917960.001]
  • [Cites] J Clin Oncol. 2004 Dec 1;22(23):4683-90 [15570070.001]
  • [Cites] J Clin Pharmacol. 2003 Oct;43(10):1124-35 [14517195.001]
  • [Cites] Nat Med. 1996 Apr;2(4):461-2 [8597958.001]
  • [Cites] Semin Cancer Biol. 1990 Apr;1(2):99-106 [2103492.001]
  • [Cites] Adv Dent Res. 1998 Nov;12(2):114-8 [9972133.001]
  • [Cites] Int J Cancer. 1997 Aug 7;72(4):556-64 [9259391.001]
  • [Cites] Histol Histopathol. 2003 Oct;18(4):1035-40 [12973672.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3296-302 [12947065.001]
  • [Cites] J Natl Cancer Inst. 1997 Sep 3;89(17):1260-70 [9293916.001]
  • [Cites] Adv Dent Res. 1998 Nov;12(2):12-26 [9972117.001]
  • [Cites] J Rheumatol. 1998 Sep;25(9):1807-12 [9733464.001]
  • [Cites] Br J Cancer. 1999 May;80(5-6):733-43 [10360651.001]
  • [Cites] J Clin Oncol. 2001 Feb 1;19(3):785-91 [11157032.001]
  • [Cites] Anticancer Res. 2003 Jan-Feb;23(1B):639-45 [12680160.001]
  • [Cites] J Immunol. 1999 Sep 15;163(6):3459-67 [10477618.001]
  • [Cites] APMIS. 1999 Jan;107(1):120-7 [10190288.001]
  • [Cites] Pharm Res. 2002 Nov;19(11):1655-62 [12458671.001]
  • [Cites] Clin Cancer Res. 2004 Oct 1;10(19):6512-21 [15475438.001]
  • (PMID = 17237909.001).
  • [ISSN] 0167-6997
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Matrix Metalloproteinase Inhibitors; 0 / Tetracyclines; 0 / tetracycline CMT-3
  •  go-up   go-down


26. Pappo AS, Devidas M, Jenkins J, Rao B, Marcus R, Thomas P, Gebhardt M, Pratt C, Grier HE: Phase II trial of neoadjuvant vincristine, ifosfamide, and doxorubicin with granulocyte colony-stimulating factor support in children and adolescents with advanced-stage nonrhabdomyosarcomatous soft tissue sarcomas: a Pediatric Oncology Group Study. J Clin Oncol; 2005 Jun 20;23(18):4031-8
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of neoadjuvant vincristine, ifosfamide, and doxorubicin with granulocyte colony-stimulating factor support in children and adolescents with advanced-stage nonrhabdomyosarcomatous soft tissue sarcomas: a Pediatric Oncology Group Study.
  • PURPOSE: To describe the response rate and survival of children and adolescents with unresected or metastatic nonrhabdomyosarcomatous soft tissue sarcomas (NRSTS) treated with vincristine, ifosfamide, and doxorubicin.
  • Granulocyte colony-stimulating factor was administered daily (5 mug/kg) after each cycle of chemotherapy.
  • RESULTS: The median patient age at diagnosis was 11.7 years; the most common primary tumor site was lower extremity (36%); and synovial sarcoma was the predominant histology.
  • Patients with synovial sarcoma had higher response rates than other patients, and patients with unresected disease had improved outcomes.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Sarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Child. Combined Modality Therapy. Doxorubicin / administration & dosage. Female. Granulocyte Colony-Stimulating Factor / administration & dosage. Humans. Ifosfamide / administration & dosage. Male. Mesna / administration & dosage. Neoadjuvant Therapy. Protective Agents / administration & dosage. Survival Analysis. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Factor II Deficiency.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2005 Jun 20;23(18):4003-5 [15767649.001]
  • (PMID = 15767644.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protective Agents; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; NR7O1405Q9 / Mesna; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


27. Brigman BE, Hornicek FJ, Gebhardt MC, Mankin HJ: Allografts about the Knee in Young Patients with High-Grade Sarcoma. Clin Orthop Relat Res; 2004 Apr;(421):232-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allografts about the Knee in Young Patients with High-Grade Sarcoma.
  • Reconstruction after resections for high-grade sarcomas about the knee in children and adolescents is a challenging problem because of the large soft tissue and skeletal defects, the effects of adjuvant therapy, and the potential for long-term use of the limb.
  • One hundred sixteen patients, all 18 years or younger, with osteosarcoma or Ewing's sarcoma located between the middle femur and middle tibia, were treated with chemotherapy, resection, and allograft reconstruction.
  • One hundred three patients with osteosarcoma and 13 patients with Ewing's sarcoma had 105 Stage II and 11 Stage III tumors.
  • Reconstruction of large bone defects about the knee in young patients who are being treated with chemotherapy is difficult.
  • [MeSH-major] Bone Neoplasms / surgery. Bone Transplantation. Knee Joint / surgery. Sarcoma, Ewing / surgery
  • [MeSH-minor] Adolescent. Child. Female. Follow-Up Studies. Humans. Male. Recovery of Function / physiology. Time Factors. Transplantation, Homologous. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Bone Grafts.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15123953.001).
  • [ISSN] 0009-921X
  • [Journal-full-title] Clinical orthopaedics and related research
  • [ISO-abbreviation] Clin. Orthop. Relat. Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


28. Raney B, Anderson J, Breneman J, Donaldson SS, Huh W, Maurer H, Michalski J, Qualman S, Ullrich F, Wharam M, Meyer W, Soft-Tissue Sarcoma Committee of the Children's Oncology Group, Arcadia, California, USA: Results in patients with cranial parameningeal sarcoma and metastases (Stage 4) treated on Intergroup Rhabdomyosarcoma Study Group (IRSG) Protocols II-IV, 1978-1997: report from the Children's Oncology Group. Pediatr Blood Cancer; 2008 Jul;51(1):17-22
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results in patients with cranial parameningeal sarcoma and metastases (Stage 4) treated on Intergroup Rhabdomyosarcoma Study Group (IRSG) Protocols II-IV, 1978-1997: report from the Children's Oncology Group.
  • PURPOSE: Determine outcome of patients with cranial parameningeal sarcoma and concurrent metastases treated on Intergroup Rhabdomyosarcoma Study Group (IRSG) Protocols II-IV.
  • PATIENTS: We identified 91 patients in the database, which includes newly diagnosed subjects <21 years old with rhabdomyosarcoma (RMS) and undifferentiated sarcoma, and reviewed their charts in detail.
  • Treatment included vincristine, actinomycin D, and cyclophosphamide (VAC) chemotherapy and radiotherapy to the primary tumor and up to five metastatic sites/tissues.
  • Sixty patients had progressive disease (N = 49) or death as a first event (N = 11); another developed myelodysplastic syndrome and died.
  • CONCLUSIONS: Cure was possible for some patients with metastatic cranial parameningeal sarcoma.
  • Distant metastases were the most frequent type of recurrence, indicating that more effective systemic agents are needed to eliminate residual disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18266224.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA-98543; United States / NCI NIH HHS / CA / CA-24507; United States / NCI NIH HHS / CA / U10 CA098413; United States / NCI NIH HHS / CA / CA-72989; United States / NCI NIH HHS / CA / U10 CA098543; United States / NCI NIH HHS / CA / CA-29511
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


29. Guo W, Ji T, Yant Y: [Endoprosthetic reconstruction after wide resection of sarcoma in lower extremities]. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2006 Oct;20(10):970-4
MedlinePlus Health Information. consumer health - Bone Grafts.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Endoprosthetic reconstruction after wide resection of sarcoma in lower extremities].
  • OBJECTIVE: To assess the clinical outcome of the limb salvage surgery and complications occurring in the lower extremities after a wide resection of sarcoma.
  • METHODS: A total of 167 patients underwent a limb-sparing procedure by means of the implantation of a custom-made or modular tumor endoprosthesis from July 1997 to July 2004.
  • In 5 patients, a proximal femur prosthesis was implanted; in 57 patients, a distal femur prosthesis was implanted; and in 38 patients, a proximal tibia prosthesis was implanted.
  • According to the Enneking staging, 3 patients were grouped in the stage of II A, 85 in I B, and 12 in III.
  • All the patients received chemotherapy for 1-2 courses and 3-5 courses before operation and after operation, respectively.
  • Local recurrence developed in 7 patients within 6 months to 2 years after operation.
  • Of the 7 patients, 4 had a recurrence of the soft tissue tumor for which resection was performed; the other 3 patients underwent amputation of the diseased limb.

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17140065.001).
  • [ISSN] 1002-1892
  • [Journal-full-title] Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery
  • [ISO-abbreviation] Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


30. Demiralp B, Ozdemir MT, Erler K, Basbozkurt M: Type 1 neurofibromatosis and adult extremity sarcoma. A report of two cases. Acta Orthop Belg; 2007 Jun;73(3):403-7
Genetic Alliance. consumer health - Neurofibromatosis type 1.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Type 1 neurofibromatosis and adult extremity sarcoma. A report of two cases.
  • We report two cases of malignant soft-tissue tumours--one myxoid malignant fibrous histiocytoma and one pleomorphic rhabdomyosarcoma--which were diagnosed in two young adult patients with type 1 neurofibromatosis (NF 1).
  • The tumours were stage II and III respectively.
  • Both patients were treated with radiotherapy or chemotherapy and surgical intervention.
  • Thus detection of subtypes of rhabdomyosarcoma and malignant fibrous histiocytoma with immunohistochemistry may be helpful for the management of these tumours among other pleomorphic sarcomas that may occur in type 1 Neurofibromatosis.
  • [MeSH-major] Histiocytoma, Malignant Fibrous / complications. Neoplasms, Multiple Primary. Neurofibromatosis 1 / complications. Rhabdomyosarcoma / complications. Soft Tissue Neoplasms

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17715736.001).
  • [ISSN] 0001-6462
  • [Journal-full-title] Acta orthopaedica Belgica
  • [ISO-abbreviation] Acta Orthop Belg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


31. Polish Paediatric Solid Tumours Study Group, Bień E, Stachowicz-Stencel T, Kazanowska B, Balcerska A, Balwierz W, Chybicka A, Dłuzniewska A, Drozyńska E, Kurylak A, Matysiaks M, Krawczuk-Rybak M, Rychłowska M, Solarz E, Sopyło B, Stencels D, Wachowiaks J, Wieczorek M, Woźniak W, Wysocki M: [Genitourinary soft tissue sarcomas located outside bladder and prostate in children treated according to the CWS-96 protocol--report from the Polish Paediatric Solid Tumours Study Group]. Med Wieku Rozwoj; 2005 Jul-Sep;9(3 Pt 2):507-15
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Genitourinary soft tissue sarcomas located outside bladder and prostate in children treated according to the CWS-96 protocol--report from the Polish Paediatric Solid Tumours Study Group].
  • AIM: Analysis of therapy efficacy in non-bladder/prostate genitourinary sarcomas in children treated from I'1997 to VI'2003 with CWS-96 protocol in Poland.
  • 63% presented with low stage neoplasm (I - 7, II - 5).
  • Primary tumour exceeded 5cm and/or invaded surrounding tissues in 7 patients (37%).
  • Six of 7 patients with macroscopic tumour residues responded to chemotherapy (CR-4, GR-2).
  • One patient (stage III triton tumour of uterus) did not, respond but obtained complete remission after mutilating delayed surgery.
  • Radiotherapy (23,5-54 Gy) was given to 8 patients.
  • 3 children developed local relapse, 3 patients died (16%): 2 due to neoplasm progression, 1 of neutropenia-related sepsis.
  • 2) chemotherapy and radiotherapy were accompanied by severe but transient myelosupression in the HR group.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Rhabdomyosarcoma / diagnosis. Rhabdomyosarcoma / drug therapy. Sarcoma / diagnosis. Sarcoma / drug therapy. Urogenital Neoplasms / diagnosis. Urogenital Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Humans. Infant. Lymphatic Metastasis. Male. Neoplasm Staging. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16719163.001).
  • [Journal-full-title] Medycyna wieku rozwojowego
  • [ISO-abbreviation] Med Wieku Rozwoj
  • [Language] pol
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


32. Hensley ML: Update on gemcitabine and docetaxel combination therapy for primary and metastatic sarcomas. Curr Opin Oncol; 2010 Jul;22(4):356-61
Hazardous Substances Data Bank. DOCETAXEL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Update on gemcitabine and docetaxel combination therapy for primary and metastatic sarcomas.
  • PURPOSE OF REVIEW: The combination of fixed-dose-rate gemcitabine and docetaxel has become an established treatment option for advanced uterine leiomyosarcoma and has demonstrated efficacy in nonleiomyosarcoma histology soft-tissue sarcomas.
  • The activity of this regimen in advanced uterine leiomyosarcoma, other soft-tissue sarcomas, and pediatric sarcomas is discussed.
  • RECENT FINDINGS: Fixed-dose-rate gemcitabine and docetaxel achieved high objective response rates in three prospective phase II studies as first-line or second-line therapy for advanced uterine leiomyosarcoma.
  • In a randomized trial, the combination of gemcitabine and docetaxel was superior to gemcitabine alone in terms of objective response, progression-free, and overall survival among patients with soft-tissue sarcoma, most of whom had received at least one prior cytotoxic regimen.
  • In a prospective phase II trial, four of 10 pediatric patients with sarcomas achieved complete responses with this regimen.
  • In a small, prospective phase II trial for women with completely resected stage I, II, III, or IV high-grade uterine leiomyosarcoma, adjuvant treatment with gemcitabine-docetaxel was associated with a 2-year progression-free survival rate that appears superior to that of historical controls.
  • SUMMARY: Fixed-dose-rate gemcitabine and docetaxel is a reasonable treatment option for patients with advanced soft-tissue sarcoma.
  • The regimen is a good choice as first-line or second-line therapy for advanced uterine leiomyosarcoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Sarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Disease-Free Survival. Humans. Taxoids / administration & dosage. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20520541.001).
  • [ISSN] 1531-703X
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 0W860991D6 / Deoxycytidine; 15H5577CQD / docetaxel; B76N6SBZ8R / gemcitabine
  • [Number-of-references] 34
  •  go-up   go-down


33. Wiener ES, Anderson JR, Ojimba JI, Lobe TE, Paidas C, Andrassy RJ, Raney RB, Qualman SJ, Donaldson SS, Maurer HM, Link MP, Crist WM, Grier HE: Controversies in the management of paratesticular rhabdomyosarcoma: is staging retroperitoneal lymph node dissection necessary for adolescents with resected paratesticular rhabdomyosarcoma? Semin Pediatr Surg; 2001 Aug;10(3):146-52
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The Intergroup Rhabdomyosarcoma Study Group (IRSG) required ipsilateral RPLND (IRPLND) for all patients with PTRMS treated on IRS-III (1984-91), but changed to clinical evaluation of RPLNs using computerized tomography (CT) in IRS-IV (1991 through 1997).
  • Nodal radiation therapy was administered only to patients with RPLNs recognized as positive; such patients received more intensive chemotherapy as well.
  • METHODS: Eligible patients with group I or II PTRMS who were treated on IRS III (n = 100) or IRS IV (n = 134) were analyzed.
  • RESULTS: There was a significant change in the distribution of patients with group I versus II tumors from IRS-III to IRS-IV (group I, 68% in IRS-III versus 82% in IRS-IV).
  • This was the result of decreased node recognition when CT was used to stage RPLNs in IRS-IV and was most notable for adolescents (>10 years of age).
  • Furthermore, adolescents with recognized group II tumors experienced better 3-year FFS than those with group I tumors on IRS-IV (100% versus 68%, P =.06), most likely as a result of receiving radiotherapy and intensified chemotherapy.
  • Furthermore, adolescent boys with group I tumors experienced worse FFS than those with Group II tumors on IRS-IV, probably because some patients with group II tumors were not identified by CT imaging and thus received less effective therapy.
  • These data suggest that adolescents should have ipsilateral RPLN dissection as part of their routine staging, and those with positive lymph nodes require intensified chemotherapy as well as nodal irradiation.
  • [MeSH-major] Lymph Node Excision. Neoplasm Staging. Retroperitoneal Space / surgery. Rhabdomyosarcoma / drug therapy. Rhabdomyosarcoma / surgery
  • [MeSH-minor] Adolescent. Chemotherapy, Adjuvant. Child. Child, Preschool. Humans. Male. Survival Rate / trends. Testicular Neoplasms. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 by W.B. Saunders Company
  • (PMID = 11481652.001).
  • [ISSN] 1055-8586
  • [Journal-full-title] Seminars in pediatric surgery
  • [ISO-abbreviation] Semin. Pediatr. Surg.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA24507; United States / NCI NIH HHS / CA / CA72989
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


34. Xu J, Sun H, Xiao Y: [Application of medial head gastrocnemius muscle flap to limb-salvage operation of proximal tibial malignant tumor]. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2007 Apr;21(4):352-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Among them, there were 4 patients with osteosarcoma, 6 with malignant fibrous histocytoma, 1 with malignant giant cell tumor, 1 with synovial sarcoma, and 1 with Ewing's sarcoma.
  • According to the Enneking staging system, 1 case was in Stage I B, 9 in Stage II A, and 3 in Stage II B.
  • One or two cycles of neoadjuvant chemotherapy were used to each of the patients before operation.
  • All of the patients underwent the medial head of the gastrocnemius muscle flap transposition to reconstruct the soft tissues after resection of the tumors and reconstruction of the bone defect by prothesis or bone-graft or the two methods combined.
  • The patient with Ewing's sarcoma had a local tumor recurrence 18 months after operation; though treated with the focal cleaning and the bone cement filling, the patient still developed lung metastasis of the tumor 26 months after operation.
  • CONCLUSION: The flap transposition of the medial head of the gastrocnemius muscle can reconstruct the soft tissue defect, decrease the local complication rate and improve the clinical outcome of the limb salvage for the proximal tibia malignant tumor.
  • [MeSH-major] Bone Neoplasms / surgery. Limb Salvage / methods. Osteosarcoma / surgery. Soft Tissue Injuries / surgery. Surgical Flaps / blood supply. Tibia
  • [MeSH-minor] Adolescent. Adult. Arthroplasty, Replacement, Knee. Bone Transplantation / methods. Female. Follow-Up Studies. Humans. Male. Middle Aged. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17546876.001).
  • [ISSN] 1002-1892
  • [Journal-full-title] Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery
  • [ISO-abbreviation] Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


35. Meza JL, Anderson J, Pappo AS, Meyer WH, Children's Oncology Group: Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the Children's Oncology Group. J Clin Oncol; 2006 Aug 20;24(24):3844-51
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: The outcome for localized rhabdomyosarcoma (RMS) or undifferentiated sarcoma (UDS) is affected by age, histology, primary anatomic site, extent of disease, and therapy.
  • RESULTS: The estimated 5-year failure-free survival (FFS) rate was 90% for patients with embryonal RMS (ERMS) stage 1, group I or IIa; stage 2, group I; or group III orbit.
  • The estimated 5-year FFS rate was 87% for patients with ERMS stage 1, group IIb or IIc; stage 1, group III nonorbit; stage 2, group II; and stage 3, group I or II; and 73% for patients with ERMS stage 2 or 3, group III.
  • The estimated 5-year FFS rate was poor for patients with stage 2 or 3, group III ERMS with invasive (T2) tumors who were age younger than 1 year or 10 years or older (56%) and patients with stage 2 or 3, group III extremity primary tumors (43%).
  • However, the 5-year FFS rate was good for patients with ARMS/UDS at favorable sites with group I or II (80%) or group III (76%) disease.
  • The FFS rate was poorer for patients with ARMS/UDS at unfavorable sites with group I or II (66%) or group III (45%) disease.
  • CONCLUSION: Patient and disease characteristics identify distinct subsets with different outcomes, allowing the Soft Tissue Sarcoma Committee of the Children's Oncology Group to refine risk-adapted therapy assignment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Rhabdomyosarcoma / therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Cisplatin / administration & dosage. Cyclophosphamide / administration & dosage. Dactinomycin / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Drug Administration Schedule. Etoposide / administration & dosage. Female. Humans. Ifosfamide / administration & dosage. Infant. Infusions, Intravenous. Male. Neoplasm Staging. Predictive Value of Tests. Prognosis. Risk Assessment. Risk Factors. Survival Analysis. Treatment Outcome. Vincristine / administration & dosage

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16921036.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-24507; United States / NCI NIH HHS / CA / CA-72989
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


36. Terenziani M, D'Angelo P, Bisogno G, Boldrini R, Cecchetto G, Collini P, Conte M, De Laurentis T, Ilari I, Indolfi P, Inserra A, Piva L, Siracusa F, Spreafico F, Tamaro P, Lo Curto M: Teratoma with a malignant somatic component in pediatric patients: the Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) experience. Pediatr Blood Cancer; 2010 Apr;54(4):532-7
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PROCEDURE: The Associazione Italiana Ematologia Oncologia Pediatrica identified 14 cases of TMSC.
  • RESULTS: The series (9 female, 5 male) showed the following disease: testis (2), sacrococcygeal (3), ovary (3), retroperitoneum (3), mediastinum (2), and foot soft tissue (1).
  • Distribution of the somatic component was: carcinoma (4), pancreatic neuroendocrine tumor (1), neuroblastoma (3), rhabdomyosarcoma (3), rhabdomyosarcoma plus liposarcoma, chondrosarcoma, neurogenic sarcoma (1), chondrosarcoma plus neuroectodermal sarcoma (1), malignant peripheral nerve sheath tumor (1).
  • Three patients were in stage I, four in stage II, three in stage III, and four in stage IV.
  • Chemotherapy optimized for histology should include reagents directed to the somatic malignancy, if chemosensitive.
  • Malignant GCT warrants GCT-directed chemotherapy.
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Humans. Infant. Infant, Newborn. Italy. Male. Neoplasm Staging. Prognosis. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Teratoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20049928.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Belgaumi AF, Al-Kofide A, Sabbah R, Shalaby L: Precursor B-cell lymphoblastic lymphoma (PBLL) in children: pattern of presentation and outcome. J Egypt Natl Canc Inst; 2005 Mar;17(1):15-9
Genetic Alliance. consumer health - Lymphoblastic lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One patient had a soft tissue mass in the upper thigh while one patient had a solitary bone lesion in the distal tibia.
  • Four of the patients had limited stage disease (2 stage I and stage II), while 2 were stage IV.
  • Both patients with stage IV disease had CNS involvement with blasts in the CSF.
  • Five patients were treated according to B-cell NHL type protocols.
  • Because of the specific diagnosis of PBLL, two of these patients were switched to an ALL-type protocol following post induction intensification; one died in remission due to encephalitis, while the other remained in CR almost 2 years after diagnosis.
  • A third patient suffered a loco-regional relapse 17 months after completing first line therapy, and was re-treated on an ALL-type protocol, and currently is in remission 25 months following relapse.
  • The fourth patient, who received 9 months of post induction therapy, remains free of disease 7 years following diagnosis.
  • The fifth patient had local and CNS progression on therapy, and died of his disease.
  • The last patient with a solitary bone lesion was misdiagnosed as Ewings' Sarcoma and received treatment for that disease.
  • He suffered an isolated CNS relapse, and is in CR 12 months following the relapse, on an ALL treatment protocol.
  • Patients should not be treated on short intensive protocols used for other B-cell NHL but should receive treatment based on ALL protocols like those for treating T-cell LL.
  • [MeSH-major] B-Lymphocytes / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Humans. Male. Neoplasm Staging. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16353078.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  •  go-up   go-down






Advertisement